Health Policy

This cross-sectional study examines changes in the market concentration of hospitals affiliated with group purchasing organizations between 2014 and 2024.

This cohort study reports on participation by nephrologists in mandatory and voluntary value-based kidney care models and the association with home dialysis use.

This cohort study assesses risk factors for obstetric unit closure and closure of entire hospitals providing obstetric services.

This Special Communication compares policies regarding cognitive decline in aging physicians among the US, Canada, and the other Group of Seven (G7) countries and how these countries manage age-related cognitive risks in other safety-critical fields.

This Viewpoint discusses state and federal regulatory restrictions on physician dual fee schedules and cash-based pricing and describes associated increases in health care costs.

This JAMA Forum discusses the promise and limits of health savings accounts, the reasons why market competition alone is not the answer, and ideas for promoting value and affordability.

This cohort study analyzes the extent to which rising health insurance premiums reflect growth in health spending vs growth in markups in the large-group market, small-group market, and in the health insurance exchanges for privately insured individuals.

This cross-sectional study used Current Procedural Terminology codes and 2023 claims data to compare preventive care rates across Medicaid managed care organizations and employer-sponsored, Marketplace, and Medicare Advantage plans in Virginia.

This cross-sectional study examines the association between insurance type and mental health service utilization among US adults with chronic pain.

This randomized clinical trial examines whether teenagers and young adults perceive that social media warnings discourage them from wanting to use social media and increase their awareness of the harms of social media.

This Viewpoint describes potential concerns and opportunities with a single-trial default for US Food and Drug Administration (FDA) drug approval.

This JAMA Forum discusses Medicaid work requirements after passage of the 2025 budget reconciliation law, the role of artificial intelligence (AI) in helping to determine Medicaid eligibility, and potential guardrails in the use of AI tools to determine eligibility in each state.

This Viewpoint outlines implementation principles intended to protect individuals with medical frailty from unintended coverage disruption because of new policy under the budget reconciliation act of 2025 (HR 1).

This cross-sectional study uses Medicare data to compare 2 definitions of safety-net ambulatory practices to investigate the extent to which safety-net practices overlap.

This survey study investigates laypeople’s reactions to finding out that their clinician’s performance metrics may be based on the percentage of patients who undergo cancer screenings.

This cross-sectional study examines prior authorization processing times and approval rates for branded medication prescriptions that were initially rejected, and assesses key factors associated with variation in these outcomes.

This review evaluates the FDA Sentinel Initiative’s Active Risk Identification and Analysis system use and challenges amid ongoing plans to modernize it through the forthcoming Prescription Drug User Fee Act.

This Viewpoint proposes an expansion of state-run prescription-drug monitoring programs to meet the need for broader pharmacovigilance given the shift to alternative payment methods that bypass traditional insurance claims.

This JAMA Forum discusses the possibilities of using artificial intelligence to speed up the clinical trial process and accelerate the discovery and delivery of new treatments.